|
|
|
| Comparison of the Treatment Outcomes for Retinopathy of Prematurity with an Intravitreal Injection of Conbercept or Ranibizumab |
| Zonghua Wang1, Qiuping Li2, Xiumei Yang1, Huimin Zhang3 |
1Department of Ophthalmology, the Seventh Medical Center of PLA General Hospital, Beijing 100700,China
2Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing 100700,China
3Department of Ophthalmology, Senior Department of Ophthalmology, the Third Medical Center of PLA General Hospital, Beijing 100039, China |
|
|
|
| Guide |
|
|
Abstract Objective:To analyze the treatment ef?cacy of an intravitreal injection of conbercept (IVC) or ranibizumab (IVR) for type 1 retinopathy of prematurity (ROP).Methods:In this retrospectively case-control study,clinical records of 45 preterm infants (86 eyes) treated by IVC and 62 preterm infants (122 eyes) treated by IVR were retrospectively analyzed from January 2017 to June 2019. The intraocular in?ammatoryreaction,ROP disease regression and recurrence were observed regularly after the operation. In the IVC group, therewere 16 cases (32 eyes) in zone I and 29 cases (54 eyes) in zone II; In the IVR group, there were 23 cases (46 eyes) in zone I and 39 cases (76 eyes) in zone II. At-test and Chi-square test were used for data analysis.Results:There were no signi?cant differences in gender, gestational age, birth weight, corrected gestational age, lesion zoning or aggressive posterior retinopathy of prematurity between the two groups.The recurrence of treatment rates for IVR and IVC were 45% and 35%, respectively, of which 61% and 63% were in zone I, and 37% and 19% in zone II. The time of recurrence of treatment after injection was 8.8±2.5 and 11.2±3.1 weeks in zone II, and the difference is insigni?cant. There were signi?cant differencesin the rate of recurrence between the two groups (χ2=5.214,P=0.024).Conclusions:Intravitreal injection of conbercept and ranibizumab is an effective choice for ROP. The recurrence after treatment is related to the lesion area, the rate of recurrence was lower after injection of comber cept in zone II, but long-term safety needs to be evaluated further.
|
|
Received: 08 February 2021
|
|
|
| Fund:The Innovation and Cultivation Fund of the Seventh Medical Center of the PLA General Hospital (2016-PY-LC-008) |
|
Corresponding Authors:
Zonghua Wang, Department of Ophthalmology, the Seventh Medical Center of PLA General Hospital, Beijing 100700, China (Email: zonghuaw2002@163.com)
|
|
|
|
| [1] |
Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol, 2003, 121(12): 1684-1694. DOI: 10.1001/archopht.121.12.1684.
|
| [2] |
Cavallaro G, Filippi L, Bagnoli P, et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol, 2014, 92(1): 2-20. DOI: 10.1111/aos.12049.
|
| [3] |
M u e l l e r B , S a l c h o w D J , Wa ff e n s c h m i d t E , e t a l . Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol, 2017, 101(3): 365-370. DOI: 10.1136/ bjophthalmol-2016-308375.
|
| [4] |
Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology, 2015, 122(5): 1008-1015. DOI: 10.1016/ j.ophtha.2014.12.017.
|
| [5] |
Hartnett ME. Role of cytokines and treatment algorithms in retinopathy of prematurity. Curr Opin Ophthalmol, 2017, 28(3): 282-288. DOI: 10.1097/ICU.0000000000000360.
|
| [6] |
VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American academy of ophthalmology. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
|
| [7] |
Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina, 2014, 34 Suppl 12: S1-S18. DOI: 10.1097/ IAE.0000000000000399.
|
| [8] |
Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet, 2019, 394(10208): 1551- 1559. DOI: 10.1016/S0140-6736(19)31344-3.
|
| [9] |
Kennedy KA, Mintz-Hittner HA. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. JAAPOS, 2018, 22(1): 61-65.e1. DOI: 10.1016/ j.jaapos.2017.10.006. Epub 2017 Dec 6.
|
| [10] |
Alyamaç Sukgen E, Çömez A, Koçluk Y, et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica, 2016, 236(3): 139-147. DOI: 10.1159/000449530.
|
| [11] |
Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity.Ophthalmol Retina, 2018, 2(9): 942-948. DOI: 10.1016/j.oret.2018.01.017.
|
| [12] |
Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina, 2017, 37(4): 694-701. DOI: 10.1097/IAE.0000000000001209.
|
| [13] |
Zhang J, Liang Y, Xie J, et al. Conbercept for patients with age-related macular degeneration: a systematic review. BMC ophthalmol, 2018, 18(1): 142. DOI: 10.1186/s12886-018-0807-1.
|
| [14] |
程湧, 梁建宏, 黎晓新. 康柏西普玻璃体腔注射治疗急进性后 极部早产儿视网膜病变的疗效观察. 中华眼底病杂志, 2017, 33(2): 144-147. DOI: 10.3760/cma.j.issn.1005-1015.2017. 02.008.
|
| [15] |
张海涛, 万素华, 靳玮, 等. 康柏西普玻璃体腔注射治疗早产 儿视网膜病变的疗效观察及其影响因素分析. 中华眼底病杂志, 2019, 35(2): 171-175. DOI: 10.3760/cma.j.issn.1005-1015. 2019.02.012.
|
| [16] |
Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther, 2015, 9: 2311-2320. DOI: 10.2147/DDDT.S67536.
|
| [17] |
Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: Anatomic outcomes and influencing factors. Ophthalmology, 2017, 124(8): 1156-1164. DOI: 10.1016/j.ophtha.2017.03.018.
|
| [18] |
Hu Q, Bai Y, Chen X, et al. Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study. J Ophthalmol, 2017, 2017: 5078565. DOI: 10.1155/2017/5078565.
|
| [19] |
Lorenz B, Stieger K, Jäger M, et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treatsevere posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina, 2017, 37(1): 97-111. DOI: 10.1097/IAE.0000000000001126.
|
| [20] |
Li Z, Zhang Y, Liao Y, et al. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol, 2018, 18(1): 19. DOI: 10.1186/ s12886-018-0685-6.
|
| [21] |
Pertl L, Steinwender G, Mayer C, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One, 2015, 10(6): e0129383. DOI: 10.1371/ journal.pone.0129383.
|
|
|
|
